Browse Studies — Arctuva

Phase 2

TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line trea…

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Brown UniversityNCT07502872

Phase 1

Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lym…

Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Jonsson Comprehensive Cancer CenterNCT05256641

Phase 1

A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refra…

B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Vironexis Biotherapeutics Inc.